Industry News

Biotechnology Industry News

Vivek Ramaswamy has found time out…

December 16th, 2025|FierceBiotech|

Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech. The new firm, Ambros Therapeutics, launched Tuesday with a $125 million series A and plans to develop

The FDA has delayed an approval…

December 16th, 2025|FierceBiotech|

The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially reach the market.

A flurry of deal-making hasn’t…

December 16th, 2025|FierceBiotech|

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.

Xoma, which styles itself as a…

December 16th, 2025|FierceBiotech|

Xoma, which styles itself as a “biotech royalty aggregator,” has struck a deal to acquire Generation Bio for roughly $4.29 per share at the time of the planned merger’s close.

Sanofi is back with its second…

December 15th, 2025|FierceBiotech|

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease.

MapLight Therapeutics is the…

December 15th, 2025|FierceBiotech|

MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. The neuro-focused company is penning a strategic collaboration meant to develop new therapies for central nervous system diseases.

Aviceda Therapeutics has hit a…

December 15th, 2025|FierceBiotech|

Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy, an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay

Cell therapy company Link Cell…

December 15th, 2025|FierceBiotech|

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue.

Seattle’s Adaptive…

December 15th, 2025|FierceBiotech|

Seattle’s Adaptive Biotechnologies is linking up with Pfizer on two non-exclusive pacts that leverage the biotech’s bespoke T-cell receptor discovery engine and large-scale immune receptor antigen-mapping data. At the same time, Dren Bio said it

AI drug developer Chai Discovery…

December 15th, 2025|FierceBiotech|

AI drug developer Chai Discovery has brewed up a $130 million series B to juice its development of a “computer-aided design suite” for new therapeutics.

Immunome’s investigational oral…

December 15th, 2025|FierceBiotech|

Immunome’s investigational oral therapy slashed the risk of disease progression or death by 84% for patients with desmoid tumors, data one analyst is deeming a “near best-case outcome.”

Kyverna Therapeutics looks all the…

December 15th, 2025|FierceBiotech|

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” benefits for the company’s CD19 agent

After spending the year angling…

December 15th, 2025|FierceBiotech|

After spending the year angling for a new approval in multiple sclerosis, Sanofi's stockings may hang empty this holiday season—at least when it comes to tolebrutinib in non-relapsing secondary progressive multiple sclerosis.

Fresh off a $153 million series E…

December 15th, 2025|FierceBiotech|

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Swedish biopharma Sobi.

After a year marked by dramatic…

December 12th, 2025|FierceBiotech|

After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current momentum—as long as strong clinical data continue to be rewarded and companies can bring drugs

Zealand Pharma may be gearing up…

December 12th, 2025|FierceBiotech|

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success.

A key late-stage trial of Arcus…

December 12th, 2025|FierceBiotech|

A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several trials of the drug.

Cycle Pharmaceuticals is circling…

December 12th, 2025|FierceBiotech|

Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.